Bioinformatics analysis suggests that <i>COL4A1</i> may play an important role in gastric carcinoma recurrence

Li, De Feng; Wang, Nan Nan; Chang, Xin; Wang, Shu Ling; Wang, Lisheng; Yao, Jun; Li, Zhao Shen

doi:10.1111/1751-2980.12758

Cited by 19 publications

(16 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have shown that COL4A1 is essential in tumorigenesis, which contributes to the proliferation, migration and colony formation in many cancers ( Huang et al, 2018 ; Jin et al, 2017 ). COL4A1 has been identified as one of the prognostic biomarkers of several diseases, whose high expression level is usually associated with poor overall survival (consistent with our result HR = 1.332) ( Huang et al, 2018 ; Li et al, 2019 ; Sulpice et al, 2013 ). Another marker, COL4A2 , is involved in proliferation and migration of endothelial cells and induces apoptosis ( JingSong et al, 2017 ).…”

Section: Discussionsupporting

confidence: 91%

Transcriptome analysis reveals a reprogramming energy metabolism-related signature to improve prognosis in colon cancer

Zhang

Lan

et al. 2020

PeerJ

View full text Add to dashboard Cite

Although much progress has been made to improve treatment, colon cancer remains a leading cause of cancer death worldwide. Metabolic reprogramming is a significant ability of cancer cells to ensure the necessary energy supply in uncontrolled proliferation. Since reprogramming energy metabolism has emerged as a new hallmark of cancer cells, accumulating evidences have suggested that metabolism-related genes may serve as key regulators of tumorigenesis and potential biomarkers. In this study, we analyzed a set of reprogramming energy metabolism-related genes by transcriptome analysis in colon cancer and revealed a five-gene signature that could significantly predict the overall survival. The reprogramming energy metabolism-related signature could distinguish patients into high-risk and low-risk groups with significantly different survival times (P = 0.0011; HR = 1.92; 95% CI [1.29–2.87]). Its prognostic value was confirmed in another two independent colon cancer cohorts (P = 5.2e–04; HR = 2.09, 95%; CI [1.37–3.2] for GSE17538 and P = 3.8e−04; HR = 2.08, 95% CI [1.37–3.16] for GSE41258). By multivariable analysis, we found that the signature was independent of clinicopathological features. Its power in promoting risk stratification of the current clinical stage was then evaluated by stratified analysis. Moreover, the signature could improve the power of the TNM stage for the prediction of overall survival and could be used in patients who received adjuvant chemotherapy. Overall, our results demonstrated the important role of the reprogramming energy metabolism-related signature in promoting stratification of high-risk patients, which could be diagnostic of adjuvant therapy benefit.

show abstract

Section: Discussionsupporting

confidence: 91%

Transcriptome analysis reveals a reprogramming energy metabolism-related signature to improve prognosis in colon cancer

Zhang

Lan

et al. 2020

PeerJ

View full text Add to dashboard Cite

show abstract

“…COL5A2 has been identified as a hub gene in multiple biological analyses of GC, and enrich in EMT-related pathway [44]. In another example, COL4A1 may confer trastuzumab resistance and promote gastric carcinoma recurrence in GC [45,46]. Zhang et al prior studies reported TREM2 is high expression in GC, and significantly associated with clinicopathological characteristics and prognosis [47].…”

Section: Discussionmentioning

confidence: 99%

“…Cai et al study proved that GPX3 affected migration and invasion through NFкB/Wnt5a/JNK pathway in GC [39]. The key genes COL1A1, COL4A1, COL5A2 belong to the collagen family, which is a constituent of the ECM component of tumors, and is closely related to tumor proliferation, invasion, drug resistance, and prognosis [7,[40][41][42][43][44][45][46]. For example, the high expression of COL1A1 promotes cell proliferation, invasion, and migration in GC [42].…”

Section: Discussionmentioning

confidence: 99%

High expression of TREM2 promotes EMT via the PI3K/AKT pathway in gastric cancer: bioinformatics analysis and experimental verification

Hou

Yuan

et al. 2021

J. Cancer

View full text Add to dashboard Cite

Background: To date, the pathogenesis of gastric cancer (GC) remains unclear. We combined public database resources and bioinformatics analysis methods, explored some novel genes and verified the experiments to further understand the pathogenesis of GC and to provide a promising target for anti-tumor therapy. Methods: We downloaded the chip data related to GC from the Gene Expression Omnibus (GEO) database, extracted differentially expressed genes (DEGs), and then determined the key genes in the development of GC via PPI networks and model analysis. Functional annotation via GO and KEGG enrichment of DEGs was used to understand the latent roles of DEGs. The expression of the triggering receptor expressed on myeloid cells 2 (TREM2) gene in GC cell lines was verified via RT-PCR and western blotting. Moreover, the CCK-8, wound healing assay, and transwell migration and invasion assays were used to understand the changes in the proliferation, migration, and invasion abilities of GC cells after silencing TREM2. Western blotting verified the interaction between TREM2 and PI3K predict of the string website, as well as the effect of TREM2 on EMT. Finally, a lung metastasis model was used to explore the relationship between TREM2 and metastasis. Results: Our study identified 16 key genes, namely BGN,

show abstract

“…A previous study reported that mutations in COL4A1 may affect glycine residues in the protein, which is not conducive for its structural and functional stability (13). COL4A1 mutations may cause several diseases, including those pertaining to the cardiovascular, cerebrovascular, renal, gastrointestinal and circulatory systems (14)(15)(16)(17)(18)(19). Studies have indicated that abnormal expression of COL4A1, as a novel oncogene, is closely associated with the occurrence, development and outcome of a variety of cancer types (14,16,20,21).…”

Section: Col4a1 As a Novel Oncogene Associated With The Clinical Characteristics Of Malignancy Predicts Poor Prognosis In Gliomamentioning

confidence: 99%

COL4A1 as a novel oncogene associated with the clinical characteristics of malignancy predicts poor prognosis in glioma

Wang

Liu

et al. 2021

Exp Ther Med

View full text Add to dashboard Cite

Studies have indicated that collagen α-1 (IV) chain (COL4A1) has an indispensable regulatory role in the complex pathological mechanisms of numerous types of malignant tumor. However, its role in the development of glioma has remained elusive. Therefore, the present study sought to determine the association between the expression levels of COL4A1 and the clinical characteristics of gliomas by analyzing large samples. First, analysis of thousands of glioma tissue samples collected from the Gene expression profiling interactive analysis, Gene Expression Omnibus database, the Ivy glioblastoma atlas, The Human Protein Atlas, Chinese Glioma Genome Atlas and The Cancer Genome Atlas. In addition, glioma tissues and normal brain tissues from patients with glioma and epilepsy undergoing surgical resection were collected. These samples, which were subjected to a variety of different detection techniques (including sequencing data, chip data, reverse transcription-quantitative PCR, cell lines and tissue samples, in situ hybridization and immunology) revealed that COL4A1 expression was not only increased at the mRNA level but also at the protein level as compared with that in normal brain tissue. Furthermore, Kaplan-Meier analysis revealed that COL4A1 expression was associated with reduced overall survival of patients, particularly those with World Health Organization grade III glioma. Receiver operating characteristic analysis suggested that COL4A1 had a moderate diagnostic value for glioma. In addition, the Mann-Whitney U-test or Kruskal-Wallis test indicated that the expression levels of COL4A1 were positively associated with the histological type and historical grade of the tumor, patient age, 'Primary, Recurrent, Secondary' type and the chemotherapy status, and negatively associated with isocitrate dehydrogenase mutation and 1p19q co-deletion (P<0.001). Gene-set enrichment analysis indicated that overexpression of COL4A1 promoted cancer-associated pathways, such as the JAK/STAT signaling pathway and cell cycle regulation. Finally, an MTT assay, immunohistochemical analysis of the cell cycle regulator KI67 and a wound-healing assay further confirmed that knockdown of COL4A1 inhibited the proliferation and migration ability of glioma cells. In conclusion, COL4A1, as a novel oncogene, is a marker for poor prognosis in patients with glioma. The present study expanded the understanding of the pathogenesis of glioma and identified COL4A1 as a potential target for the diagnosis and treatment of gliomas.

show abstract

Bioinformatics analysis suggests that COL4A1 may play an important role in gastric carcinoma recurrence

Cited by 19 publications

References 37 publications

Transcriptome analysis reveals a reprogramming energy metabolism-related signature to improve prognosis in colon cancer

Transcriptome analysis reveals a reprogramming energy metabolism-related signature to improve prognosis in colon cancer

High expression of TREM2 promotes EMT via the PI3K/AKT pathway in gastric cancer: bioinformatics analysis and experimental verification

COL4A1 as a novel oncogene associated with the clinical characteristics of malignancy predicts poor prognosis in glioma

Contact Info

Product

Resources

About